MMP9 and osteosarcoma: We suggested that the antimetastatic effect of aprepitant in osteosarcoma is probably attributed to its ability to modulate the transcriptional regulator, NF-κB, and subsequently, its target genes, including MMP-2, MMP-9, and VEGF-A.